Publications
Detailed Information
Cancer screening using (18)F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeong Won | - |
dc.contributor.author | Kang, Keon Wook | - |
dc.contributor.author | Paeng, Jin Chul | - |
dc.contributor.author | Lee, Sang Mi | - |
dc.contributor.author | Chung, June-Key | - |
dc.contributor.author | Lee, Dong Soo | - |
dc.contributor.author | Lee, Myung Chul | - |
dc.contributor.author | Jang, Su Jin | - |
dc.date.accessioned | 2012-07-03T07:00:53Z | - |
dc.date.available | 2012-07-03T07:00:53Z | - |
dc.date.issued | 2009-09 | - |
dc.identifier.citation | ANNALS OF NUCLEAR MEDICINE; Vol.23 7; 685-691 | ko_KR |
dc.identifier.issn | 0914-7187 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78278 | - |
dc.description.abstract | This study was performed to evaluate the clinical value of (18)F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) for cancer screening in Korean asymptomatic people. Between February 2004 and December 2006, 1,587 asymptomatic individuals underwent FDG PET/CT as part of a cancer screening program with some other diagnostic tests at the healthcare center of our hospital. After excluding patients with a history of malignant tumor, 1,336 subjects were enrolled. All PET/CT images were visually analyzed. In subjects showing positive findings for PET/CT or other screening tests, further diagnostic tests and pathological confirmation were performed. Of the 1,336 subjects, malignant tumors were found in 16 participants (1.2%, thyroid cancer: 9, lung cancer: 2, stomach cancer: 2, and others: 4). There were 47 cases (3.6%) of positive PET/CT findings-11 cases were true positive (thyroid cancer: 8, lung cancer: 1, renal cancer: 1, and invasive thymoma), and 36 false positive, and five cases were false negative. The overall detection rate of PET/CT was 0.8%, and the sensitivity, specificity, positive-predictive value, and negative-predictive value of PET/CT were 68.8, 97.2, 23.4, and 99.6%, respectively. Fluorodeoxyglucose positron-emission tomography has the potential to detect various kinds of malignant tumors in cancer screening test, and the overall detection rate of PET/CT was 0.8%. FDG PET/CT can be a useful cancer screening modality with the selection of high-risk group and appropriate combination with other screening modalities. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPRINGER | ko_KR |
dc.subject | (18)F-fluorodeoxyglucose | ko_KR |
dc.subject | Positron-emission tomography | ko_KR |
dc.subject | Cancer screening | ko_KR |
dc.title | Cancer screening using (18)F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이정원 | - |
dc.contributor.AlternativeAuthor | 강건욱 | - |
dc.contributor.AlternativeAuthor | 팽진철 | - |
dc.contributor.AlternativeAuthor | 이상미 | - |
dc.contributor.AlternativeAuthor | 장수진 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.contributor.AlternativeAuthor | 이명철 | - |
dc.contributor.AlternativeAuthor | 이동수 | - |
dc.identifier.doi | 10.1007/s12149-009-0291-z | - |
dc.citation.journaltitle | ANNALS OF NUCLEAR MEDICINE | - |
dc.description.citedreference | Terauchi T, 2008, ANN NUCL MED, V22, P379, DOI 10.1007/s12149-008-0130-7 | - |
dc.description.citedreference | KO D, 2008, NUCL MED MOL IMAGING, V42, P444 | - |
dc.description.citedreference | Minamimoto R, 2007, ANN NUCL MED, V21, P481, DOI 10.1007/s12149-007-0061-8 | - |
dc.description.citedreference | Cook GJR, 2007, Q J NUCL MED MOL IM, V51, P235 | - |
dc.description.citedreference | Kojima S, 2007, EUR J CANCER, V43, P1842, DOI 10.1016/j.ejca.2007.05.010 | - |
dc.description.citedreference | Ghotbi N, 2007, ASIAN PAC J CANCER P, V8, P93 | - |
dc.description.citedreference | Ono K, 2007, ANN NUCL MED, V21, P65 | - |
dc.description.citedreference | Brix G, 2005, J NUCL MED, V46, P608 | - |
dc.description.citedreference | Weckesser M, 2005, EUR J NUCL MED MOL I, V32, P342, DOI 10.1007/s00259-005-1775-2 | - |
dc.description.citedreference | Chen YK, 2004, ANTICANCER RES, V24, P4103 | - |
dc.description.citedreference | Rohren EM, 2004, RADIOLOGY, V231, P305, DOI 10.1148/radiol.2312021185 | - |
dc.description.citedreference | Bar-Shalom R, 2003, J NUCL MED, V44, P1200 | - |
dc.description.citedreference | Stahl A, 2003, EUR J NUCL MED MOL I, V30, P288, DOI 10.1007/s00259-002-1029-5 | - |
dc.description.citedreference | Shen YY, 2003, NEOPLASMA, V50, P217 | - |
dc.description.citedreference | Barratt A, 2002, J EPIDEMIOL COMMUN H, V56, P899 | - |
dc.description.citedreference | Yasuda S, 2000, BRIT J CANCER, V83, P1607, DOI 10.1054/bjoc.2000.1496 | - |
dc.description.citedreference | Charron M, 2000, CLIN NUCL MED, V25, P905 | - |
dc.description.citedreference | Higashi K, 1998, J NUCL MED, V39, P1016 | - |
dc.description.citedreference | Deloar HM, 1998, EUR J NUCL MED, V25, P565 | - |
dc.description.citedreference | *ICRP, 1991, ICRP PUBL, V60 | - |
dc.description.citedreference | *WHO, WHO FACT SHEETS | - |
dc.description.tc | 4 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.